2019 - Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacitidine. Brammer J.E., Boles A.E., Mansour A., Freud A.G., Mathé-Allainmat M., Quéméner A., Mortier E., Porcu P., and Mishra A. Conference: 61th ASH Annual meeting. Orlando, Florida, USA. Blood 134 (Supplement 1): 3776.

2019 - BTN2A, a New Immune-Checkpoint Targeting Vg9Vd2 T Cell Cytotoxicity. Cano C.E., Pasero C.,De Gassart A., Hoet R., Scotet E., Mortier E., Quéméner A., Rafia C., Briantais A., Le Floch A.-C., and Olive D.   Conference: 61th ASH Annual meeting. Orlando, Florida, USA. Blood 134 (Supplement 1): 1044.

2016 - A novel IL-2 and IL-15 antagonist shifting the immune balance towards tolerance: Potential therapeutic applications‎. Meghnem D.Morisseau S., Trillet K., Frutoso M., Barbieux I., Quéméner A., Jacques Y., and Mortier E. Cancer Immunol. Res. 11:4 ‏ Supplement: ‏ S     Meeting Abstract: ‏ B033.

2016 – Optimization of IL-15-based immunotherapy using an original IL-15 agonist. Frutoso M., Morisseau S., Meghnem D., Khaddage S., Jacques Y., and Mortier E.  Conference: 4th Annual Meeting of The International-Cytokine-and-Interferon-Society (ICIS).  San Francisco, CA, USA.  Cytokine. 87:94. ‏ Meeting Abstract: ‏ P083

2014 - RLI, a sushi-IL-15R alpha/IL-15 fusion protein, is a potent immunomodulatory agent on NK and CD8+T cells and synergizes with anti-PD1 treatment in preclinical mouse tumor models‎. Desbois M., Beal C., Coutzac C., Terme M., Teppaz G., Morisseau S., Béchard D., Mortier E., and Chaput N. Conference: 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR). ‏ San Diego, CA, USA. Cancer Res. 74:19 S Meeting Abstract: ‏ 25.

2011 -  Development of two IL15 immunocytokines targeting either GD2- or CD20-tumoral bearing cells. Vincent M.Teppaz G.Solé V.Bessard A., Loisel S., Watier H., Clémenceau B., Vié H., Birklé S., Garrigue-Antar L.Quéméner A., and Jacques Y.  9th Joint Meeting of the International Society for Interferon and Cytokine Research and the International Cytokine Society. Florence (Italy). Cytokine56(1):102.

2010 - Different dynamics of IL-15R activation following IL-15 cis- or trans-presentation‎ Perdreau H., Mortier E., Bouchaud G., Sole V., Boublik Y., Jacques Y., and Plet A.  Conference: 8th Joint Conference of the International-Cytokine-Society/International-Society-for-and-Cytokine-Research. ‏ Chicago, IL, USA. Cytokine. 52:1-2.

2009 - High antitumor activity of RLI, an IL15-IL15Ralpha fusion protein, in metastatic melanoma and colorectal cancerBessard A.Solé V.Bouchaud G.Quéméner A., and Jacques Y.  Annual Meeting of the Society for Leukocyte Biology, International Cytokine Society, & International Society for Interferon and Cytokine Research, Lisbonne (Portugal). Cytokine. 48(1):105.

2008 - The exon 3-encoded domain of IL-15Ralpha contributes to IL-15 high-affinity binding and is crucial for IL-15 antagonistic effect of soluble IL-15Ralpha‎. Bouchaud G., Garrigue-Antar L., Sole V., Quéméner A., Boublik Y., Mortier E., Perdreau H., Jacques Y., and Plet A.  Conference: 7th Joint Conference of the International-Cytokine-Society/International-Society-for-Interferon-and-Cytoklin-Research. Montreal, Canada.  Cytokine. 43:3.

2008 - Release of the soluble alpha chain of IL-15 receptor: a new tumor evasion mechanism associated with poor clinical outcome in head and neck cancer patients‎. Badoual C., Bouchaud G., Agueznay NEH, Mortier E., Hans S., Gey A., Fernani F., Peyrard S., Puig P.L., Bruneval P., Sastre X., Plet A., Garrigue-Antar L., Quintin-Colonna F., Fridman WH, Brasnu D., Jacques Y., and Tartour E. Virchows Arch. 452:S1.

2008 - IL-15 and IL-15 soluble receptor in Crohn's disease active patients before and after infliximab treatment‎. Bourreille A., Bouchaud G., Mortier E., Plet A., Galmiche J.P., and Jacques Y. Gastroenterology.134 :4S1